March 2024

OPHTHALMOLOGY

PROTEOMIMETIC POLYMERS SHOW ANTI-ANGIOGENIC ACTIVITY IN AMD MOUSE MODEL

​Featuring: ​Gregory W. Schwartz, PhD, and Jeremy A. Levine, MD, PhD

A new study featuring Gregory W. Schwartz, PhD, and Jeremy A. Levine, MD, PhD, both of Northwestern Medicine Ophthalmology, explores a potential breakthrough in the treatment of neovascular age-related macular degeneration (nAMD), a leading cause of irreversible vision loss.

This research team developed protein-like polymers (PLPs) that effectively inhibit the abnormal growth of blood vessels associated with nAMD. These PLPs, particularly the block copolymer Co-P1, reduced choroidal sprouting and laser-induced choroidal neovascularization in ex vivo and in vivo mouse models. The PLPs demonstrated resistance to degradation and had a prolonged half-life after injection. This study offers hope for a novel and more effective treatment for nAMD.

Read the study on Science Advances.
Gregory W. Schwartz, PhD, the Derrick T. Vail Professor of Ophthalmology
Jeremy A. Levine, MD, PhD, Assistant Professor of Ophthalmology
​

Refer a Patient

Northwestern Medicine welcomes the opportunity to collaborate with you in caring for your patients. ​

You May Also Like